Click Therapeutics
Click Therapeutics is redefining modern medicine with patient-centric digital treatments. Operating at the intersection of biology and technology, it combines neuroscience with software to create new ways to treat disease. The company develops, validates, and commercializes software as prescription medical treatments for unmet medical needs, aiming to provide safe and effective digital therapeutics globally.
Industries
Nr. of Employees
medium (51-250)
Click Therapeutics
New York, New York, United States, North America
Products
CT-152 (Rejoyn)
A prescription digital therapeutic delivered as a regulated mobile application indicated as an adjunctive treatment for symptoms of major depressive disorder; supported by randomized clinical trial evidence and regulatory authorization.
CT-132
A prescription digital therapeutic for the preventive treatment of episodic migraine delivered via a regulated mobile application; supported by pivotal randomized controlled trial data and company-reported FDA marketing authorization.
AspyreRx
A prescription digital therapeutic authorized for use in type 2 diabetes delivered as a prescription software treatment focused on behavioral and therapeutic interventions.
CT-155
A prescription digital therapeutic candidate targeting negative symptoms of schizophrenia that has advanced to pivotal clinical evaluation and has received an FDA expedited designation as reported by the sponsor.
Portfolio of earlier-stage and discovery digital therapeutic programs
Multiple investigational digital therapeutic programs across therapeutic areas (including psychiatry, neurology, metabolic disease, immunology, oncology, and cardiometabolic disease) at discovery and early clinical phases.
CT-152 (Rejoyn)
A prescription digital therapeutic delivered as a regulated mobile application indicated as an adjunctive treatment for symptoms of major depressive disorder; supported by randomized clinical trial evidence and regulatory authorization.
CT-132
A prescription digital therapeutic for the preventive treatment of episodic migraine delivered via a regulated mobile application; supported by pivotal randomized controlled trial data and company-reported FDA marketing authorization.
AspyreRx
A prescription digital therapeutic authorized for use in type 2 diabetes delivered as a prescription software treatment focused on behavioral and therapeutic interventions.
CT-155
A prescription digital therapeutic candidate targeting negative symptoms of schizophrenia that has advanced to pivotal clinical evaluation and has received an FDA expedited designation as reported by the sponsor.
Portfolio of earlier-stage and discovery digital therapeutic programs
Multiple investigational digital therapeutic programs across therapeutic areas (including psychiatry, neurology, metabolic disease, immunology, oncology, and cardiometabolic disease) at discovery and early clinical phases.
Services
Software-enhanced drug co-development service
Collaborative service to design and deliver drug–software combination treatments integrating software interventions with pharmacotherapies, including regulatory, clinical, and technical development support.
Clinical development and trial execution for digital therapeutics
Design and management of clinical studies (including decentralized and randomized controlled designs) to validate safety and efficacy of mobile app–delivered treatments and to generate regulatory-grade evidence.
Regulatory and quality systems support for regulated software products
Regulatory planning, submission support, and quality management aligned to medical device and drug–software combination frameworks, including SaMD design controls and information security practices.
Software-enhanced drug co-development service
Collaborative service to design and deliver drug–software combination treatments integrating software interventions with pharmacotherapies, including regulatory, clinical, and technical development support.
Clinical development and trial execution for digital therapeutics
Design and management of clinical studies (including decentralized and randomized controlled designs) to validate safety and efficacy of mobile app–delivered treatments and to generate regulatory-grade evidence.
Regulatory and quality systems support for regulated software products
Regulatory planning, submission support, and quality management aligned to medical device and drug–software combination frameworks, including SaMD design controls and information security practices.
Expertise Areas
- Prescription mobile application therapeutics
- Drug–software combination (software-enhanced) therapy development
- Clinical trial design and decentralized trial conduct
- Regulatory strategy and SaMD compliance
Key Technologies
- Mobile application–based therapeutics
- AI / machine learning for personalization and analytics
- Neuromodulatory audiovisual / haptic / cognitive interventions
- Digital biomarker derivation